AIP
ESPR

Ahrens Investment Partners’s Esperion Therapeutics ESPR Stock Holding History

Ahrens Investment Partners’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		$1.59K Buy
+1,000
New +$5.16K ﹤0.01% 911
2022
Q3 		– Sell
-2,000
Closed -$13K – 394
2022
Q2 		$13K Hold
2,000
– – 0.01% 586
2022
Q1 		$9K Hold
2,000
– – ﹤0.01% 751
2021
Q4 		$10K Buy
+2,000
New +$16K ﹤0.01% 741

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return

Ahrens Investment Partners's ESPR Position: Q1 2023 in Review

Ahrens Investment Partners opened a new position in Esperion Therapeutics (ESPR) in Q1 2023: 1,000 shares worth $1.59K. The stake represents ﹤0.01% of the portfolio and ranks #911 among its holdings. This is a return to the name: Ahrens Investment Partners previously reported a position in ESPR as recently as Q2 2022.

Ahrens Investment Partners first reported a position in ESPR in Q4 2021 and has held it in 4 quarters since. The position peaked at $13K in Q2 2022. 164 funds tracked by Wall St. Rank hold ESPR as of Q1 2023.

  • Ahrens Investment Partners held 1,000 shares of Esperion Therapeutics worth $1.59K as of Q1 2023.
  • Esperion Therapeutics was a new Ahrens Investment Partners position in Q1 2023.
  • Esperion Therapeutics made up ﹤0.01% of Ahrens Investment Partners's portfolio in Q1 2023, its #911 holding.
  • Ahrens Investment Partners first reported a position in Esperion Therapeutics in Q4 2021 and has held it in 4 quarters since.
  • Ahrens Investment Partners's Esperion Therapeutics position peaked at $13K in Q2 2022.
  • 164 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2023.

Based on Ahrens Investment Partners's 13F filing for Q1 2023, filed 24 Apr 2023.